Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2025
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast CancerEmmanuel F Petricoin, Denise M Wolf, Christina Yau, et al.
Cancer Research|May 19, 2005
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patientsHongyue Dai, Laura van't Veer, John Lamb, et al.
NPJ Breast Cancer|September 14, 2018
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancerMark Jesus M Magbanua, Hope S Rugo, Louai Hauranieh, et al.
Blood|May 8, 2007
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphomaLaurent Knoops, Rick Haas, Sanne de Kemp, et al.
Breast Cancer Research and Treatment|January 29, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordanceGiuseppe Viale, Leen Slaets, Femke A de Snoo, et al.
The New England Journal of Medicine|May 25, 2002
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutationsTimothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
Turning the tide against cancer through sustained medical innovation: the pathway to progressAmy Abernethy, Edward Abrahams, Anna Barker, et al.
BMC Medical Genomics|January 22, 2011
EMT is the dominant program in human colon cancerAndre Loboda, Michael V Nebozhyn, James W Watters, et al.
Antibodies (Basel, Switzerland)|November 8, 2019
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast CancerEfrat T Harel, Penelope M Drake, Robyn M Barfield, et al.
Pageof 5